Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation

Journal of Translational Medicine

Volumn 7, Issue , 2009, Pages 93-

  Carpenter, Erica L ^a   Mick, Rosemarie ^a,b   Rüter, Jens ^a,b   Vonderheide, Robert H ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD27 ANTIGEN; CD70 ANTIGEN; CD86 ANTIGEN; CP 870893; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TOLL LIKE RECEPTOR 9;

ARTICLE; B LYMPHOCYTE ACTIVATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MEMORY CELL; PROTEIN EXPRESSION; T LYMPHOCYTE; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 9;

EID: 70749083844     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-7-93     Document Type: Article

References (42)

1. Lanzavecchia A. Immunology. Licence to kill. Nature 1998, 393:413-414. 10.1038/30845, 9623994.
2. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998, 393:478-480. 10.1038/30996, 9624004.
3. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T- helper and a T-killer cell. Nature 1998, 393:474-478. 10.1038/30989, 9624003.
4. Schoenberger SP, Toes RE, Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998, 393:480-483. 10.1038/31002, 9624005.
5. French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999, 5:548-553. 10.1038/5505, 10229232.
6. Diehl L, den Boer AT, Schoenberger SP, Voort EI, Schumacher TN, Melief CJ, Offringa R, Toes RE. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999, 5:774-779. 10.1038/10495, 10395322.
7. Sotomayor EM, Borrello I, Tubb E, Rattis FM, Bien H, Lu Z, Fein S, Schoenberger S, Levitsky HI. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999, 5:780-787. 10.1038/10503, 10395323.
8. van Mierlo GJ, den Boer AT, Medema JP, Voort EI, Fransen MF, Offringa R, Melief CJ, Toes RE. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA 2002, 99:5561-5566. 122809, 11929985, 10.1073/pnas.082107699.
9. Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 2007, 13:1083-1088. 10.1158/1078-0432.CCR-06-1893, 17317815.
10. Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, Macduff BM, Anderson DM, Gimpel SD, Davis-Smith T, Maliszewski CR. Molecular and biological characterization of a murine ligand for CD40. Nature 1992, 357:80-82. 10.1038/357080a0, 1374165.
11. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000, 67:2-17.
12. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. AnnuRevImmunol 2004, 22:307-328.
13. Ahonen CL, Wasiuk A, Fuse S, Turk MJ, Ernstoff MS, Suriawinata AA, Gorham JD, Kedl RM, Usherwood EJ, Noelle RJ. Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood 2008, 111:3116-3125. 2265452, 18202224, 10.1182/blood-2007-09-114371.
14. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O'Dwyer PJ, Running KL, Huhn RD, Antonia SJ. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007, 25:876-883. 10.1200/JCO.2006.08.3311, 17327609.
15. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998, 4:627-630. 10.1038/nm0598-627, 9585241.
16. Perricone MA, Smith KA, Claussen KA, Plog MS, Hempel DM, Roberts BL, St George JA, Kaplan JM. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother 2004, 27:273-281. 10.1097/00002371-200407000-00003, 15235388.
17. Shah S, Divekar AA, Hilchey SP, Cho HM, Newman CL, Shin SU, Nechustan H, Challita-Eid PM, Segal BM, Yi KH, Rosenblatt JD. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer 2005, 117:574-586. 10.1002/ijc.21177, 15912532.
18. Inoue S, Leitner WW, Golding B, Scott D. Inhibitory effects of B cells on antitumor immunity. Cancer Res 2006, 66:7741-7747. 10.1158/0008-5472.CAN-05-3766, 16885377.
19. Kim S, Fridlender ZG, Dunn R, Kehry MR, Kapoor V, Blouin A, Kaiser LR, Albelda SM. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models. J Immunother 2008, 31:446-457. 10.1097/CJI.0b013e31816d1d6a, 18463540.
20. Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008, 224:201-214. 10.1111/j.1600-065X.2008.00661.x, 18759928.
21. Buhlmann JE, Foy TM, Aruffo A, Crassi KM, Ledbetter JA, Green WR, Xu JC, Shultz LD, Roopesian D, Flavell RA. In the absence of a CD40 signal, B cells are tolerogenic. Immunity 1995, 2:645-653. 10.1016/1074-7613(95)90009-8, 7540943.
22. Hunter TB, Alsarraj M, Gladue RP, Bedian V, Antonia SJ. An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model. Scand J Immunol 2007, 65:479-486. 10.1111/j.1365-3083.2007.01927.x, 17444959.
23. Diggle PJ, Liang KY, Zeger SL. Analysis of longitudinal data. 1994, Oxford Oxford University Press.
24. Carpenter EL, Mick R, Rech AJ, Beatty GL, Colligon TA, Rosenfeld MR, Kaplan DE, Chang KM, Domchek SM, Kanetsky PA, Fecher LA, Flaherty KT, Schuchter LM, Vonderheide RH. Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin Cancer Res 2009, 15:4277-4287. 10.1158/1078-0432.CCR-09-0537, 19549767.
25. Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bals R, Giese T, Engelmann H, Endres S, Krieg AM, Hartmann G. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001, 31:3026-3037. 10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H, 11592079.
26. Ahonen CL, Doxsee CL, McGurran SM, Riter TR, Wade WF, Barth RJ, Vasilakos JP, Noelle RJ, Kedl RM. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 2004, 199:775-784. 2212721, 15007094, 10.1084/jem.20031591.
27. Calame KL. Plasma cells: finding new light at the end of B cell development. Nat Immunol 2001, 2:1103-1108. 10.1038/ni1201-1103, 11725300.
28. Arce E, Jackson DG, Gill MA, Bennett LB, Banchereau J, Pascual V. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol 2001, 167:2361-2369.
29. Choe J, Choi YS. IL-10 interrupts memory B cell expansion in the germinal center by inducing differentiation into plasma cells. Eur J Immunol 1998, 28:508-515. 10.1002/(SICI)1521-4141(199802)28:02<508::AID-IMMU508>3.0.CO;2-I, 9521060.
30. Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu DH, Kastelein R, Moore KW, Banchereau J. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992, 89:1890-1893. 48559, 1371884, 10.1073/pnas.89.5.1890.
31. Kawano MM, Mihara K, Huang N, Tsujimoto T, Kuramoto A. Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood 1995, 85:487-494.
32. Grammer AC, Lipsky PE. CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum 2002, 46:1417-1429. 10.1002/art.10287, 12115170.
33. Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM, Johnson LL, Swain SL, Lund FE. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000, 1:475-482. 10.1038/82717, 11101868.
34. Fuchs EJ, Matzinger P. B cells turn off virgin but not memory T cells. Science 1992, 258:1156-1159. 10.1126/science.1439825, 1439825.
35. Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW, Heathcote J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004, 24:693-701. 10.1007/s10875-004-6244-3, 15622454.
36. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005, 115:739-746. 546459, 15696196.
37. Molenkamp BG, van Leeuwen PA, Meijer S, Sluijter BJ, Wijnands PG, Baars A, Eertwegh AJ, Scheper RJ, de Gruijl TD. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res 2007, 13:2961-2969. 10.1158/1078-0432.CCR-07-0050, 17504997.
38. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007, 117:1184-1194. 1857270, 17476348, 10.1172/JCI31414.
39. Molenkamp BG, Sluijter BJ, van Leeuwen PA, Santegoets SJ, Meijer S, Wijnands PG, Haanen JB, Eertwegh AJ, Scheper RJ, de Gruijl TD. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res 2008, 14:4532-4542. 10.1158/1078-0432.CCR-07-4711, 18628468.
40. Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006, 36:810-816. 10.1002/eji.200535744, 16541472.
41. Clatworthy MR, Watson CJ, Plotnek G, Bardsley V, Chaudhry AN, Bradley JA, Smith KG. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009, 360:2683-2685. 10.1056/NEJMc0808481, 19535812.
42. Wagner M, Poeck H, Jahrsdoerfer B, Rothenfusser S, Prell D, Bohle B, Tuma E, Giese T, Ellwart JW, Endres S, Hartmann G. IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J Immunol 2004, 172:954-963.